GE HealthCare (GEHC) ends 2025 with an AI imaging push, cloud deals and enterprise alliances
As of December 7, 2025, GE HealthCare Technologies Inc. is leaning hard into AI-driven imaging, cloud software and long-term clinical partnerships. New MRI and CT platforms, NVIDIA-accelerated scanners, and enterprise agreements with the University of Rochester Medical Center (URMC) and Mayo Clinic set the tone for 2026.
For healthcare leaders, the signal is clear: imaging performance, throughput and care coordination will be shaped by end-to-end software, not just hardware upgrades. The Intelerad acquisition adds an outpatient and SaaS backbone to that plan.
Company snapshot
GE HealthCare operates across Imaging, Ultrasound, Patient Care Solutions and Pharmaceutical Diagnostics. Shares recently traded near $85.46, with a market cap around $39 billion, and a 52-week range of roughly $57.65 to $94.80.
- Institutional ownership remains high (80%+ of float), reflecting steady fund participation.
- Valuation sits near a mid-teens earnings multiple, typical for large-cap medtech with steady growth.
AI takes center stage at RSNA 2025
New MRI and CT platforms
GE HealthCare introduced Signa One, an MRI platform that threads AI through planning, positioning, acquisition and reading. A live camera feed helps synchronize with breathing motion to reduce artifacts and tighten scan consistency.
- Signa Bolt: wide-bore 3T system for advanced diagnostics and research.
- Signa Sprint: 1.5T MRI with a ventless design and sealed-helium magnet using about 1% of the helium of traditional systems.
The Photonova Spectra photon-counting CT advanced into U.S. regulatory review, bringing higher-resolution spectral data and AI-assisted reconstruction for oncology and cardiology use cases.
NVIDIA inside: faster reconstruction, shorter exams
- Vivid Pioneer: an ultra-premium cardiovascular ultrasound platform using dual NVIDIA GPUs for reconstruction speed, AI quantification and high-end visualization.
- New MRI and CT platforms apply GPU acceleration for real-time image enhancement, shorter scan times and AI-driven workflow support to cut repeats and reduce patient time in the scanner.
This move targets feature parity or advantage against Siemens Healthineers and Philips by offering integrated AI platforms rather than isolated algorithms.
Imaging 360: the radiology command center
Hardware is half the story. Imaging 360 aggregates data across scanners, sites and modalities to guide operations and quality.
- System-wide view of utilization, scheduling and technologist workload.
- Machine-learning flags on protocol or exam time outliers, with suggested optimization.
- Remote collaboration and scan-assist (Imaging 360 Remote/nCommand) to support complex studies in lower-volume sites.
For radiology leaders, this replaces spreadsheet audits with real-time insight. It also supports GE's shift to recurring software revenue and dovetails with the Intelerad deal.
Strategic alliances: URMC and Mayo Clinic
Seven-year Care Alliance with URMC
- Fleet upgrades across MRI, CT, PET/CT, SPECT/CT and ultrasound.
- Precision medicine investments, including advanced visualization and molecular imaging.
- Standardized patient monitoring and connected devices across the system.
- An imaging center of excellence within URMC's Imaging Sciences department.
URMC becomes a live reference site for enterprise-scale imaging, monitoring and operations-useful for peers assessing similar system-wide upgrades.
GEMINI-RT with Mayo Clinic
- Patient-level digital twins by linking imaging, planning and dose-delivery data.
- AI-assisted plan creation to maximize tumor dose while limiting exposure to healthy tissue.
- Multi-modal data (imaging, clinical records, sensors) to improve response prediction and longer-term outcomes.
For oncology leaders, the goal is consistent planning quality, faster iteration and tighter integration between diagnostics and therapy.
Intelerad acquisition: $2.3B for outpatient and cloud imaging
GE HealthCare agreed to acquire Intelerad for $2.3 billion in cash, adding a major cloud enterprise imaging platform with strong outpatient penetration. This broadens access to radiology groups and imaging centers and expands the SaaS footprint.
- Deeper reach into a growing outpatient enterprise imaging market.
- Larger recurring revenue base and a path to orchestrate multi-vendor AI at scale.
- Expected to be accretive to growth and margins; targeted high single-digit ROIC by year five; about $270 million revenue in its first full year post-close.
Closing is planned for the first half of 2026, pending approvals. For context, see the Reuters coverage and the GE HealthCare newsroom.
Earnings check: Q3 2025
- Revenue: ~$5.14B (slightly above estimates), up mid-single digits year over year.
- Imaging devices: ~$2.35B, up 5%.
- China: sales down ~3% (~$547M) amid anti-corruption crackdowns and slower stimulus.
- Net income: ~$446M vs. ~$470M a year ago, pressured by tariffs and costs.
- Adjusted EPS: $1.07 (beat), guidance raised to $4.51-$4.63 for 2025.
- Tariffs: ~$265M headwind in 2025 (~$0.45 EPS impact).
- Profitability: net margin near 11%, ROE above 22%.
Credit profile remains investment grade (S&P BBB). Leverage and liquidity are consistent with a capital-equipment-heavy healthcare issuer.
Street view, valuation and 2026 setup
- Recent price: ~$85.46; trailing P/E ~17.7; PEG ~3.5; dividend yield ~0.2%.
- Consensus rating: Moderate Buy; average 12-month target near $86-$89, implying limited near-term upside.
- Recent broker actions: selective target increases tied to AI imaging updates and RSNA momentum.
Forecasts point to steady mid-single-digit revenue growth and margin expansion through the decade. Average 2025 EPS estimates sit near $4.6, with an upward trend modeled beyond 2025.
What healthcare leaders can do next
- Map an upgrade path for Signa One and photon-counting CT; quantify helium, siting and venting savings for 1.5T replacements.
- Pilot Imaging 360 at one high-variance site; measure throughput, no-show reduction and repeat rates.
- Stand up governance for AI protocols, credentialing and exception handling; include medical physics, IT security and quality.
- If your enterprise uses Intelerad, plan for platform roadmaps, data migration guardrails and vendor-neutral AI integration.
- Coordinate with radiation oncology on digital-twin-style planning workflows; define handoffs from diagnostic imaging to therapy.
- Pressure-test cybersecurity and PHI safeguards for remote operations and multi-site data aggregation.
- Account for tariff-linked cost variability in capital plans and supplier negotiations.
If your team needs structured upskilling on AI tooling and workflows, explore focused learning paths by job role here: Complete AI Training - Courses by Job.
Key themes and risks for 2026
- Growth drivers: NVIDIA-accelerated scanners, Signa One, Photonova Spectra and Imaging 360 push GE toward full-stack imaging and informatics. The Intelerad deal and enterprise alliances build recurring software revenue and reference sites.
- Trade exposure: Tariffs remain a known drag; expanded duties on metals or specific countries would pressure margins.
- China volatility: Policy actions and demand swings could offset strength in the U.S. and EMEA.
- Integration risk: Folding a sizable SaaS business into an equipment-centric operation requires tight execution across product, culture and sales.
- Competition: Siemens Healthineers and Philips are investing in similar end-to-end AI workflows, keeping pricing and innovation pressure high.
- Valuation/expectations: With shares near consensus targets, further upside likely depends on outperformance in growth or margins-or a broader shift in how investors price AI-heavy medtech.
Bottom line
GE HealthCare is moving from hardware-first to platform-led imaging and oncology. New scanners, an AI-centric workflow stack, and marquee alliances with URMC and Mayo Clinic point to tighter clinical integration and software-driven performance gains.
The Intelerad acquisition adds outpatient reach and a stronger SaaS core. Execution on integration, global demand and product delivery will decide how much value this strategy creates in 2026.
This article is for informational purposes only and does not constitute investment advice. Please do your own research or consult a qualified financial advisor before making investment decisions.
Your membership also unlocks:
